On the downside, GSK's COVID-19 therapy Xevudy (sotrovimab) saw a slump in demand, with sales falling to £500 million from £1.3 billion in the first quarter of 2022, and GSK is expecting the ...

GSK) announced today that the European Medicines Agency (EMA) has begun reviewing a prefilled syringe form of Shingrix, GSK's vaccine for shingles prevention. This new syringe presentation is ...

GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix for the prevention of shingles.

Between being a radio show host, a lead singer in a touring band, and an avid horseback rider, TV personality Faith Martin is living her best life. There's little downtime in Martin's active day ...

GSK plc announced that the European Medicines Agency (EMA) has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix (GSK’s Recombinant Zoster Vaccine or RZV) ...

It has been about a month since the last earnings report for GSK (GSK). Shares have added about 8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to ...

Shingrix and our vaccines pipeline will contribute meaningfully in the medium and long term. Importantly, 2025 will see further additions to GSK's portfolio with five new product approvals ...

Breakthrough Adjuvant AB-801 Secures“Bioprocessing Excellence in Taiwan” HonorTAIPEI, Taiwan, March 13, 2025 (GLOBE NEWSWIRE) ...

During this conference where the launch of the "Shingrix" vaccine was announced, Engineer Hassan Fahmi General Manager of GSK Egypt, spoke about the importance of introducing the "Shingrix ...

GlaxoSmithKline Pharma has been benefitting from rising market share for its antibiotic Augmentin and respiratory drugs Nucala and Trelegy. Strong demand for its vaccine for shingles, Shingrix ...

WHAT TO WATCH --VACCINES: Investors will eye sales figures for two of GSK's key vaccines, shingles vaccine Shingrix and respiratory syncytial virus vaccine Arexvy, both of which performed poorly ...

GSK’s fourth-quarter Vaccine sales declined 12% due to lower sales of its RSV vaccine Arexvy and shingles vaccine, Shingrix. Arexvy generated £158 million during the quarter, down 69% year ...